Qi Jingshu, Ping Dabing, Sun Xin, Huang Kai, Peng Yuan, Liu Chenghai
Institute of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Institute of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
J Ethnopharmacol. 2023 Jul 15;311:116419. doi: 10.1016/j.jep.2023.116419. Epub 2023 Mar 30.
Fuzheng Huayu formula (FZHY), composed of Salvia miltiorrhiza Bunge, Cordyceps sinensis, the seed of Prunus persica (L.) Batsch, the pollen of Pinus massoniana Lamb, Gynostemma pentaphyllum (Thunb.) Makino and the fruit of Schisandra chinensis (Turcz.) Baill, is a Chinese herbal compound with demonstrated clinical benefits in liver fibrosis (LF). However, its potential mechanism and molecular targets remain to be elucidated.
This study was designed to evaluate the anti-fibrotic role of FZHY in hepatic fibrosis and to elucidate the potential mechanisms.
Network pharmacology was assayed to identify the interrelationships among compounds of FZHY, potential targets and putative pathways on anti-LF. Then the core pharmaceutical target for FZHY against LF was verified by serum proteomic analysis. Further in vivo and in vitro assays were performed to verify the prediction of the pharmaceutical network.
The network pharmacology analysis revealed that a total of 175 FZHY-LF crossover proteins were filtered into a protein-protein interaction (PPI) network complex and designated as the potential targets of FZHY against LF, and the Epidermal Growth Factor Receptor (EGFR) signaling pathway was further explored according to the Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis. Then analytical studies were validated by carbon tetrachloride (CCl)-induced model in vivo. We found FZHY could attenuate CCl-induced LF, especially decrease p-EGFR expression in α-Smooth Muscle Actin (α-SMA)-positive hepatic stellate cell (HSC) and inhibit the downstream of the EGFR signaling pathway, especially Extracellular Regulated Protein Kinases (ERK) signaling pathway in liver tissue. We further demonstrate that FZHY could inhibit Epidermal Growth Factor (EGF)-induced HSC activation, as well as the expression of p-EGFR and the key protein of the ERK signaling pathway.
FZHY has a good effect against CCl-induced LF. The action mechanism was associated with the down-regulation of the EGFR signaling pathway in activated HSCs.
扶正化瘀方(FZHY)由丹参、冬虫夏草、桃仁、马尾松花粉、绞股蓝和五味子组成,是一种在肝纤维化(LF)治疗中显示出临床疗效的中药复方。然而,其潜在机制和分子靶点仍有待阐明。
本研究旨在评估扶正化瘀方在肝纤维化中的抗纤维化作用,并阐明其潜在机制。
采用网络药理学方法,确定扶正化瘀方各成分、潜在靶点与抗肝纤维化假定通路之间的相互关系。然后通过血清蛋白质组学分析验证扶正化瘀方抗肝纤维化的核心药物靶点。进一步进行体内和体外实验,以验证药物网络的预测结果。
网络药理学分析显示,共有175种扶正化瘀方-肝纤维化交叉蛋白被筛选进入蛋白质-蛋白质相互作用(PPI)网络复合体,被确定为扶正化瘀方抗肝纤维化的潜在靶点。根据京都基因与基因组百科全书(KEGG)分析,进一步探索了表皮生长因子受体(EGFR)信号通路。然后通过四氯化碳(CCl)诱导的体内模型对分析研究进行验证。我们发现扶正化瘀方可减轻CCl诱导的肝纤维化,特别是降低α-平滑肌肌动蛋白(α-SMA)阳性肝星状细胞(HSC)中p-EGFR的表达,并抑制肝组织中EGFR信号通路的下游,特别是细胞外调节蛋白激酶(ERK)信号通路。我们进一步证明,扶正化瘀方可抑制表皮生长因子(EGF)诱导的HSC活化,以及p-EGFR和ERK信号通路关键蛋白的表达。
扶正化瘀方对CCl诱导的肝纤维化有良好疗效。其作用机制与激活的HSCs中EGFR信号通路的下调有关。